Kyverna Therapeutics, Inc. (KYTX)
NASDAQ: KYTX · Real-Time Price · USD
3.330
-0.100 (-2.92%)
At close: Jan 17, 2025, 4:00 PM
3.360
+0.030 (0.90%)
After-hours: Jan 17, 2025, 7:48 PM EST
Kyverna Therapeutics Cash Flow Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| TTM
| FY 2023 | FY 2022 | FY 2021 |
| Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| Net Income | -110.66 | -60.37 | -28.89 | -26.35 |
| Depreciation & Amortization | 2.03 | 1.71 | 1.05 | 0.59 |
| Loss (Gain) From Sale of Assets | - | - | - | 0.02 |
| Loss (Gain) From Sale of Investments | -6.03 | -1.12 | -0.28 | - |
| Stock-Based Compensation | 7.76 | 2.22 | 0.93 | 0.25 |
| Other Operating Activities | 2.31 | 1.72 | 1.41 | 7.83 |
| Change in Accounts Payable | 9.01 | 4.08 | 0.68 | 0.01 |
| Change in Unearned Revenue | - | - | -7.03 | -5.66 |
| Change in Other Net Operating Assets | -0.18 | -0.66 | -3.98 | 1.16 |
| Operating Cash Flow | -95.75 | -52.41 | -36.11 | -22.16 |
| Capital Expenditures | -2.01 | -0.62 | -0.77 | -1.29 |
| Investment in Securities | -156.44 | -8.16 | -13.33 | - |
| Investing Cash Flow | -158.44 | -8.79 | -14.1 | -1.29 |
| Long-Term Debt Repaid | - | -0.78 | -0.25 | -0.04 |
| Net Debt Issued (Repaid) | -0.93 | -0.78 | -0.25 | -0.04 |
| Issuance of Common Stock | 341.67 | 0.65 | 0.18 | 0.03 |
| Other Financing Activities | -4.85 | -1.65 | - | - |
| Financing Cash Flow | 335.89 | 58.12 | 11.88 | 72.52 |
| Net Cash Flow | 81.7 | -3.08 | -38.33 | 49.08 |
| Free Cash Flow | -97.76 | -53.03 | -36.88 | -23.44 |
| Free Cash Flow Margin | - | - | -525.00% | -414.50% |
| Free Cash Flow Per Share | -3.53 | -78.73 | -80.97 | -88.17 |
| Cash Interest Paid | 0.16 | 0.19 | 0.07 | 0 |
| Levered Free Cash Flow | -56.08 | -29.74 | -23.54 | - |
| Unlevered Free Cash Flow | -55.98 | -29.63 | -23.5 | - |
| Change in Net Working Capital | -11.33 | -6.07 | 6.35 | - |
Source: S&P Capital IQ. Standard template.
Financial Sources.